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Introduction: Comprehensively evaluating the efficacy and safety of high-frequency oscillatory ventilation (HFOV) is
important to allow clinicians who are using or considering this intervention to make appropriate decisions.
Methods: To find randomized controlled trials (RCTs) comparing HFOV with conventional mechanical ventilation
(CMV) as an initial treatment for adult ARDS patients, we searched electronic databases (including PubMed, MedLine,
Springer Link, Elsevier Science Direct, ISI web of knowledge, and EMBASE) with the following terms: “acute respiratory
distress syndrome”, “acute lung injury”, and “high frequency oscillation ventilation”. Additional sources included
reference lists from the identified primary studies and relevant meta-analyses. Two investigators independently
screened articles and extracted data. Meta-analysis was conducted using random-effects models.
Results: We included 6 RCTs with a total of 1,608 patients in this meta-analysis. Compared with CMV, HFOV did not
significantly reduce the mortality at 30 or 28 days. The pooled relative risk (RR) was 1.051 (95% confidence interval (CI)
0.813 to 1.358). ICU mortality was also not significantly reduced in HFOV group, with a pooled RR of 1.218 (95% CI 0.925
to 1.604). The pooled effect sizes of HFOV for oxygenation failure, ventilation failure and duration of mechanical ventilation
were 0.557 (95% CI 0.351 to 0.884), 0.892 (95% CI 0.435 to 1.829) and 0.079 (95% CI −0.045 to 0.203), respectively. The risk
of barotrauma and hypotension were similar between the CMV group and HFOV group, with a RR of 1.205 (95% CI 0.834
to 1.742) and a RR of 1.326 (95% CI 0.271 to 6.476), respectively.
Conclusions: Although HFOV seems not to increase the risk of barotrauma or hypotension, and reduces the risk of
oxygenation failure, it does not improve survival in adult acute respiratory distress syndrome patients.Introduction
Both acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are life-threatening conditions that are
usually associated with substantial morbidity [1,2], mortal-
ity [3], and financial costs [4]. Conventional mechanical
ventilation (CMV) is still considered the cornerstone of
treatment for these patients. However, although mechanical* Correspondence: yong_song6310@yahoo.com
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unless otherwise stated.ventilation can initially sustain life, it may cause further
lung injury [5-8].
To avoid ventilator-induced lung injury, lung-protective
ventilation has been recommended, which focused on
avoiding cyclic alveolar collapse and re-expansion, pre-
venting alveolar excess distension, and achieving and
maintaining alveolar recruitment [9-11]. High-frequency
oscillation is an alternative mechanical ventilation method
that delivers very small tidal volumes at high frequencies
(3 to 15 Hz) using an oscillatory pump [12]. High-
frequency oscillatory ventilation (HFOV) can not only
avoid over-distension of alveoli by delivering small tidalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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collapse and maintain alveolar recruitment by applying
a constant airway pressure [13-15]. Therefore, HFOV
theoretically achieves all goals pursued by lung-protective
ventilation strategies [11,16,17].
However, no more than six randomized controlled trials
(RCTs) in adult ARDS patients have been published on
the safety and efficacy of HFOV as an initial treatment
strategy. Three previous trials comparing HFOV with
CMV suggested that HFOV improved both oxygenation
and survival in adults with ARDS [18-20], but two recent
larger-scale RCTs presented different or even opposite
results [21,22]. Therefore, this approach remains an
unproven and controversial therapy for adults with
ARDS [23-26].
Two Cochrane reviews examining the effect of HFOV
on mortality in ALI/ARDS patients have been published.
The earlier one found only two small RCTs and was not
powerful enough to draw definitive conclusions [27]; the
later study [28] concluded that HFOV might improve
survival, which was not completely consistent with the
conclusions of two recently published large RCTs [21,22].
Neither of the above two Cochrane reviews focused on
the effect of HFOV in unique adults with ARDS. Since
two large scale RCTs comparing HFOV with CMV as an
initial treatment for unique adult ARDS patients have
been recently published, we performed a meta-analysis of
RCTs, to systematically review the efficacy and safety of




We performed a meta-analysis of published RCTs com-
paring HFOV with CMV for ALI/ARDS in unique adult
patients. All analyses were based on published data
extracted from the six eligible studies, which have been
approved by the Institutional Review Committee on
Human Research. An additional file shows this in more
detail (see Additional file 1). Additionally, as described in
the six primary studies, all patients (or their representatives)
enrolled in these six trials have provided written informed
consent before any study-related procedure was performed.
Therefore, the present meta-analysis does not present
any further problems in relation to ethics or conflicts of
interest.
Literature search and identification of the publications
To identify all published RCTs comparing HFOV with
CMV in adult ARDS patients, a search of electronic
databases (including PubMed, MedLine, Springer Link,
Elsevier Science Direct, ISI web of knowledge, and
EMBASE) was carried out with the following terms:
acute respiratory distress syndrome; acute lung injury;high frequency oscillation ventilation. There were no
language restrictions. This search was conducted through
July 2013, with no additional time limits. The reference
lists of the identified primary studies and relevant meta-
analyses were also searched for additional studies.
To be included in the present meta-analysis, studies
had to be RCTs comparing HFOV with CMV, enrolling
unique adult ALI/ARDS patients, and reporting at least
one of the following outcomes of interest: ICU mortality;
28- or 30-day mortality; hypoxemia and ventilation failure;
duration of mechanical ventilation; and the incidence of
barotrauma or hypotension. All of the candidate articles
were independently read and checked for the inclusion
criteria by two investigators (XG and GW). Disagreements
were resolved through consensus. The methodological
quality of the included studies was evaluated according to
the Cochrane handbook 5.1.0 for randomized controlled
trials [29]. Given that blinding of physicians, patients or
related family members was impossible in those trials, we
compared whether rescue treatments were equally applied
in the treatment group and control group, and performed
quality assessment according to the following five aspects,
including random sequence generation, allocation con-
cealment, incomplete outcome data, selective reporting,
and others.
Data extraction
Information was extracted independently by two investiga-
tors (XG and GW) from all eligible studies. The required
items included in the data form were as follows: (1) basic
information about the primary study, including the first
author’s name, year of publication, sample size of the study,
single or multicenter design, the definition of ALI or ARDS
used, and the overall risk of bias; (2) clinically relevant
primary outcomes, including ICU mortality, 28- or 30-day
mortality, hypoxemia (including oxygenation failure and
refractory hypoxemia diagnosed in the primary eligible
studies) and ventilation failure (including ventilation failure,
acidosis, and refractory acidosis diagnosed in the primary
eligible studies), and duration of mechanical ventilation;
and (3) the incidence of barotrauma or hypotension. The
lists from the two investigators were compared, and dis-
agreements about the extracted data were resolved by
consensus.
Statistical analyses
All meta-analysis were performed by random-effects
models (the DerSimoniane and Laird method). We re-
ported continuous outcomes using standardized mean
differences with the 95% CI, and binary outcomes were
presented as relative risk with the 95% CI. The Z-test and
chi-square test were used to generate the P-value for the
continuous outcomes and for the binary outcomes, re-
spectively. P <0.05 was considered statistically significant.
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tested with the chi-square-based Q-test and quantified
with the I2 statistic (25 to 49% for low heterogeneity, 50
to 74% for moderate heterogeneity, and 75 to 100% for
high heterogeneity) [30]. Sensitivity analysis was performed
to evaluate the influence of the individual trial on the
pooled effect. Potential publication bias was investigated by
funnel plots and was formally evaluated with Egger’s linear
regression test and Begg’s adjusted rank correlation test. All
statistical analyses were performed with Stata software
(version 11.0; StataCorp LP, College Station, TX, USA)
using two-sided p values. P <0.05 was considered statis-
tically significant.
Results
Literature search and study characteristics
Using the search term high frequency oscillatory ventila-
tion combined with acute respiratory distress syndrome
or with acute lung injury, 784 citations were identified.
Among them, six trials [18-22,31] met the inclusion cri-
teria and were enrolled in the meta-analysis. The flow
chart of the identification and selection of publications
is shown in Figure 1.
Six eligible trials [18-22,31] enrolled a total of 1,608
adult patients with ARDS (Table 1). All trials investigated
HFOV as an initial treatment for ARDS rather than as a
rescue treatment after the failure of conventional venti-
lation. The tested patients in most of these trials were
continuously treated with HFOV for more than 24 hours,
except in one trial that continuously applied high-
frequency oscillation for 12 hours [20]. The controlFigure 1 Flow chart of studies included in this meta-analysis.groups in four trials underwent low-tidal-volume ventila-
tion (≤8 ml/kg) [20-22,31], whereas three trials performed
low plateau pressure (≤35 cm H2O) [20,21,31]. Among
all of the included studies, five studies with high meth-
odological quality and low risk of bias passed the quality
assessment [18,20-22,31], and the risk of bias in the sixth
trial was unclear [19] (Table 1).
Mortality at 28 or 30 days
In the primary analysis of five trials [18,19,21,22,31]
(n = 1,580), the median mortality at 30 or 28 days in
the control group and the HFOV group was 41.1%
(range 28.6 to 52.1%) and 40.4% (range 37.3 to 43.2%),
respectively. The results of the meta-analysis suggested
that HFOV did not significantly reduce mortality at 30 or
28 days in adult ARDS patients (relative risk (RR) 1.051,
95% CI 0.813, 1.358; Table 2 and Figure 2A). As significant
heterogeneity was detected among the above five enrolled
studies (I2 = 63.1%, P = 0.028), and considering the tidal
volume and plateau airway pressure might be the sources
of heterogeneity, we performed subgroup analysis strati-
fied by the tidal volume (≤8 ml/kg predicted body weight)
and by the plateau airway pressure (≤35 cmH2O) in the
control group, respectively. The results of these subgroup
analyses also suggest that HFOV failed to reduce mortality
at 30 or 28 days in adult ARDS patients. These results of
subgroup analysis and the related forest plot are shown in
Table 2 and Figure 2A, B.
Sensitivity analysis was also analyzed, and the results
demonstrated that after each study was excluded from
the overall meta-analysis, similar results were obtained
Table 1 Essential characteristics of included studies
First author Year Institute Patients (number) Details of ARDS Overall risk of bias
HFOV CMV
Derdak [18] 2002 ICUs in 13 US hospitals 75 73 ARDS; PEEP <10 cm H2O Low
Shah [31] 2004 1 ICU in Cardiff, Wales 15 13 ARDS Low
Bollen [19] 2005 5 ICUs in 4 European cities 37 24 ARDS Unclear (>10% (11/61) crossovers)
Demory [20] 2007 1 ICU in Marseille, France 13 15 ARDS; PaO2/FiO2 ≤ 150, PEEP ≥5cmH2O Low
Young [22] 2013 ICUs in England, Wales,
and Scotland
398 397 ARDS; PaO2/FiO2 ≤ 200, PEEP ≥5cmH2O Low
Ferguson [21] 2013 38 centers in Canada, the
United States, Saudi Arabia,
Chile, and India
275 273 ARDS; PaO2/FiO2 ≤ 200,FiO2 ≥ 0.5 Low
ARDS, acute respiratory distress syndrome; CMV, conventional mechanical ventilation; FiO2, fraction of inspired oxygen; HFOV, high-frequency oscillatory ventilation;
PaO2, arterial oxygen tension; PEEP, positive end expiratory pressure.
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was observed (Table 4).ICU mortality
Three eligible studies [20-22] (n = 1,371) reported ICU
mortality. The median mortality in the control group and
the HFOV group was 30.8% (range 26.7 to 42.1%) and
44.2% (range 30.8 to 44.7%), respectively. We performed a
meta-analysis using a random-effects model, and the re-
sults of this meta-analysis suggested that high-frequency
oscillatory ventilation did not significantly reduce or
increase the risk of death in ICU compared with con-





Mortality at 28 or 30 days 5 800 7
Subgroup
Tidal volume in control
group <8 ml/kg
Mandated 3 688 6
Not mandated 2 112 9
Plateau pressure in control
group <35cmH2O
Mandated 2 290 2
Not mandated 3 510 4
ICU mortality 3 686 6
CMV, conventional mechanical ventilation; HFOV, high-frequency oscillatory ventilat(RR 1.218, 95% CI 0.925, 1.604; Table 2 and Figure 2C).
However, the sensitivity analysis showed that a paradoxical
result obtained after the OSCAR trial [22] was excluded
from the overall meta-analysis, and it suggested that
HFOV would significantly increase the ICU mortality in
adult ARDS patients (RR 1.442, 95% CI 1.160, 1.792;
Table 3). Neither Egger’s test nor Begg’s test showed any
evidence of publication bias (Table 4).Oxygenation failure, ventilation failure and duration of
mechanical ventilation
Oxygenation failure was defined as persisting abnormal




80 63.1 0.028 1.051 0.704
(0.813, 1.358)
83 63.1 0.067 1.149 0.329
(0.869, 1.519)
7 56.4 0.13 0.899 0.712
(0.511, 1.582)
86 14.6 0.279 1.323 0.092
(0.955, 1.834)
94 44.7 0.164 0.942 0.665
(0.720, -1.233)
85 63.3 0.066 1.218 0.160
(0.925, 1.604)
ion; n, number; RR, relative risk.
Figure 2 Forest plots for the meta-analysis of mortality: (A) Meta-analysis of mortality at 28 or 30 days, and subgroup analyses stratified by
the tidal volume of the conventional ventilation group (in which tidal volumes ≤8 ml/kg were used or not used). (B) Meta-analysis of mortality at
28 or 30 days, and subgroup analyses stratified by the plateau pressure of the conventional ventilation group (in which plateau pressure ≤35 cmH2O was
used or not used). (C) Meta-analysis of ICU mortality. (D) Meta-analysis for oxygenation failure. (E) Meta-analysis of ventilation failure. (F) Meta-analysis for
the duration of mechanical ventilation. (G) Meta-analysis of barotrauma. (H) Meta-analysis of hypotension. LPV, lung-protective ventilations.
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Table 3 Sensitivity analysis
Excluded study Relative risk 95% CI
Mortality at 28 or 30 days
Derdak (2002) 1.164289 0.9238705, 1.4672717
Bollen (2005) 1.0212231 0.76526242, 1.3627961
Ferguson (2013) 0.94643247 0.77333957, 1.158268
Young (2013) 1.0512564 0.69253296, 1.5957943
Shah (2004) 1.0661671 0.80484247, 1.4123416
ICU mortality
Demory (2007) 1.2246462 0.89132315, 1.6826202
Ferguson (2013) 1.0530359 0.89893317, 1.2335562
Young (2013) 1.4420993 1.160399, 1.7921858
Oxygenation failure
Derdak (2002) 0.58428353 0.28815368, 1.1847403
Bollen (2005) 0.51638663 0.31883517, 0.83634168
Ferguson (2013) 0.82795441 0.31200156, 2.1971316
Ventilation failure
Derdak (2002) 1.0543551 0.4344992, 2.5584965
Bollen (2005) 0.91356009 0.43406373, 1.9227407
Ferguson (2013) 0.64884853 0.2125513, 1.9807193
Duration of mechanical ventilation
Derdak (2002) 0.09791627 −0.09584169, 0.29167423
Bollen (2005) 0.06240474 −0.06527908, 0.19008856
Young (2013) 0.15380768 −0.11983663, 0.427452
Barotrauma
Shah (2004) 1.229754 0.84895152, 1.7813679
Derdak (2002) 1.3130077 0.87979519, 1.9595348
Bollen (2005) 1.1886587 0.78003234, 1.8113472
Ferguson (2013) 0.6947636 0.29700547, 1.6252108
Hypotension
Derdak (2002) 2.6042271 0.44842839, 15.123928
Bollen (2005) 0.69353223 0.05379397, 8.9412804
Shah (2004) 0.89276189 0.0725222, 10.990066
Table 4 Publication bias
Type of meta-analysis Begg’s test
z




Duration of mechanical ventilation 1.04
Barotrauma −0.68
Hypotension −0.52
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of three eligible studies [18,19,21] (n = 757) that reported
the incidence of oxygenation failure demonstrated HFOV
significantly reduced the risk of oxygenation failure com-
pared with conventional ventilation (RR 0.557, 95% CI
0.351, 0.884; Figure 2D). The result of sensitivity analysis
showed HFOV would not significantly improve oxygen-
ation compared with CMV, when the study of Derdak [18]
or the OSCILLATE trial [21] was excluded from the over-
all meta-analysis (Table 3). It suggested that the result of
this meta-analysis for oxygenation failure was not stable,
and that further clinical trials are needed to determine
whether HFOV is more effective than CMV for the im-
provement of oxygenation in adult ARDS patients. No
publication bias of the enrolled studies was observed
(Table 4).
Three enrolled studies demonstrated the ventilation
efficiency of HFOV: one study [21] reported the incidence
of refractory acidosis, one [19] reported the occurrence of
acidosis, and the third [18] reported the incidence of ven-
tilation failure with a clear definition, that is, ‘a pH ≤ 7.15
for 6 hours and a bicarbonate of 19 meq/L or moreʼ. We
performed a meta-analysis with a random-effects model
and demonstrated that there was no significant difference
in ventilation efficiency between the HFOV group and the
control group (RR 0.892, 95% CI 0.435, 1.829; Figure 2E).
Sensitivity analysis demonstrated that after each study was
excluded from the overall meta-analysis, similar results
were obtained (Table 3). No publication bias of the en-
rolled studies was observed (Table 4).
Three eligible trials [18,19,22] (n = 1,004) provided the
duration of mechanical ventilation. The results of meta-
analysis showed that the high-frequency oscillation
strategy did not significantly reduce the duration of
mechanical ventilation (standardized mean difference
0.079, 95% CI −0.045, 0.203; Figure 2F). Sensitivity analysis
demonstrated that after each study was excluded from
the overall meta-analysis, similar results were obtained
(Table 3). No publication bias of the enrolled studies
was observed (Table 4).Egger’s test
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Barotrauma was defined as a group of symptoms caused
by the high airway pressure during mechanical ventila-
tion, such as pneumothorax, pneumomediastinum,
pneumopericardium, subcutaneous emphysema and so
on. We performed a meta-analysis to summarize the dif-
ference in the risk of barotrauma between the HFOV
group and control group. Four enrolled studies provided
the incidence of barotrauma, but they all applied differ-
ent definitions of barotrauma: only pneumothorax [31],
any pulmonary air leak [18], severe air leak resulting in
treatment failure [19], or new-onset barotrauma [21].
The above four enrolled trails reported the incidence of
barotrauma in the HFOV group as 0/15 [31], 7/75 [18],
1/37 [19], 46/256 [21] patients, respectively; and in the
CMV group as 1/13 [31], 9/73 [18], 1/24 [19], 34/259
[21] patients, respectively. The results of the meta-
analysis and the forest plot are shown in Figure 2G. The
relative risk for barotrauma was 1.205 (95% CI 0.834,
1.742). This result suggests that HFOV does not increase
or reduce the risk of barotrauma compared with CMV.
In the sensitivity analysis, similar results were obtained
after each study was excluded from the overall meta-
analysis (Table 3). No publication bias of the enrolled
studies was observed (Table 4).
Adverse event: hypotension
Three eligible trials (n = 237) reported the incidence of
hypotension in the HFOV group as 0/75 [18], 4/37 [19],
1/15 [31] patients, respectively; and in the CMV group
as 2/73 [18], 1/24 [19], 0/13 [31] patients, respectively.
The results of meta-analysis demonstrated that the HFOV
would not significantly increase the risk of hypotension
compared with CMV (RR 1.326, 95% CI 0.271, 6.476;
Figure 2H). Sensitivity analysis demonstrated that after
each study was excluded from the overall meta-analysis,
similar results were obtained (Table 3). No publication
bias of the enrolled studies was observed (Table 4).
Discussion
To the best of our knowledge, the present study is the
first meta-analysis examining the effect of HFOV in
unique adults with ARDS, although two cognate Cochrane
reviews [27,32] have been published based on studies in-
cluding mutually exclusive groups of patients, and the
more recent one [32] combined the results from adult and
pediatric patients. Importantly, the efficacy of HFOV is
likely associated with the age of the patient, as Arnold
et al. reported that patients older than five years had
dramatically increased mortality compared with patients
younger than five years, when treated with HFOV [33].
Additionally, the earlier Cochrane review [27] found only
two small RCTs and was not powerful enough to draw
definitive conclusions. Although the later one [32] includedeight randomized controlled trials with 419 patients, it in-
cluded two studies investigating the combination effect of
HFOV and additional interventions (prone positioning [34]
and tracheal gas insufflation [35]), which would complicate
the results of meta-analysis.
In the present meta-analysis of mortality, we showed
that HFOV did not significantly reduce mortality at 30
or 28 days compared with CMV. This finding contrasts
sharply with experimental studies in animals in which
benefits of high-frequency oscillation were observed
[36]. Our results may suggest that the benefits of HFOV
cannot be translated directly from animal models to
adult ARDS patients, probably because there is great
heterogeneity in the recruitability of the lung [37] and
because the well-controlled conditions of animal studies
are often difficult to replicate in human clinical trials.
Our results are also at variance with those of the latest
Cochrane review of HFOV in 2013 [32], which showed
HFOV significantly reduced in-hospital or 30-day mor-
tality compared with conventional ventilation. This may
be simply because the present meta-analysis enrolled
two more large multicenter trials and recruited more
than three times the number of patients recruited in the
previous meta-analysis. Our results are consistent with
those of two recently published large-scale RCTs, which
are known as the OSCILLATE trial [21] and OSCAR
trial [22], respectively. Sensitivity analysis showed that in
the meta-analysis of mortality at 30 or 28 days, after
each study was excluded from the overall meta-analysis,
similar results were obtained. This suggests that our
results of 30- or 28-day mortality are valid.
As moderate heterogeneity was revealed in the overall
meta-analysis of mortality, and considering that the tidal
volume and plateau airway pressure might be the sources
of heterogeneity, we performed subgroup analysis ac-
cording to the tidal volume (≤8 ml/kg predicted body
weight) and according to the plateau airway pressure
(≤35 cmH2O) in the control group, respectively. Although
the heterogeneity remained moderate after the stratifica-
tion by tidal volume, the heterogeneity was significantly
reduced when the data were stratified depending on the
control group’s plateau airway pressure. It appears that the
plateau airway pressure is one of the most possible sources
of heterogeneity. The results from these subgroup ana-
lyses all suggest that HFOV did not significantly reduce
mortality at 30 or 28 days in adult ARDS patients. This
indicates that the results of this meta-analysis are stable.
Although the meta-analysis of ICU mortality demon-
strated that HFOV did not significantly affect ICU mortal-
ity compared with CMV, the sensitivity analysis showed
that the OSCAR trial [22] drastically affected the pooled
results of our meta-analysis of ICU mortality. After the
OSCAR trial was excluded, the pooled results suggested
that the application of HFOV would significantly increase
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beneficial effect of HFOV on mortality could have been
underestimated because one study [21] enrolled 40% of
the patients included in our meta-analysis of ICU mortal-
ity, and in that study more than 10% of patients in the
control group crossed over to receive HFOV. Thus, the
result of this meta-analysis of the risk of death in ICU
was not stable, and further clinical trials are needed to
determine whether HFOV is as effective as CMV for the
improvement of ICU survival in adult ARDS patients.
The present meta-analysis showed that HFOV signifi-
cantly reduced the risk of hypoxemia compared with
CMV. This result is consistent with our meta-analysis of
the PaO2/FiO2 ratio on day 1 which demonstrated that
the application of HFOV significantly improved the
PaO2/FiO2 ratio on the first day after the initiation of
mechanical ventilation (data not shown). However, the
sensitivity analysis showed whenever the OSCILLATE
trial [21] or the study by Derdak et al. [18] was excluded,
the pooled results of the other two studies suggested that
HFOV did not significantly reduce the incidence of oxy-
genation failure. This may be simply because the other
two trials enrolled too few patients to identify a significant
difference. Thus, it is still possible that the application of
HFOV significantly improves oxygenation and reduces the
risk of hypoxemia.
There are several limitations of the present meta-
analysis. First, the six enrolled studies were published
between 2002 and 2013, which may have caused moder-
ate heterogeneity of the control group and therefore
complicated the results of this meta-analysis. Second,
the sample size of the included trials ranged from 28 to
795, which could have influenced the precision of the
pooled effect-estimates. Lastly, we only evaluated the
effect of HFOV on the incidence of barotrauma and
hypotension, therefore, the evaluation of the safety of
HFOV might not be comprehensive enough.Conclusions
The pooled analysis of the currently available data sug-
gests that HFOV does not significantly reduce mortality
at 30 or 28 days, nor does it reduce ICU mortality, although
it seems to significantly reduce the risk of oxygenation
failure in adult ARDS patients. Furthermore, HFOV has
no significant effect on the incidence of ventilation failure,
the duration of mechanical ventilation or the risk of baro-
trauma and hypotension. Although these results suggest
HFOV would not increase the incidence of barotrauma or
hypotension, they do not support the recommendation
that HFOV is used in routine care for adult patients with
ARDS. More large-scale multicenter RCTs are required to
further determine the efficacy and safety of HFOV in adult
ARDS patients.Key messages
 In adult ARDS patients, high-frequency oscillation did
not significantly reduce mortality at 30 or 28 days, or
the mortality within the ICU compared with CMV.
 Compared with conventional ventilation, HFOV,
although having no significant effect on the
incidence of ventilation failure or the duration of
mechanical ventilation, significantly reduced the risk
of oxygenation failure.
 High-frequency oscillatory ventilation was not
associated with an increased risk of barotrauma or
hypotension and seemed to be as safe as
conventional ventilation.
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